File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Favorable outcomes of unrelated cord blood transplant for pediatric acute myeloid leukemia in Hong Kong

TitleFavorable outcomes of unrelated cord blood transplant for pediatric acute myeloid leukemia in Hong Kong
Authors
KeywordsMedical sciences
Oncology medical sciences
Pediatrics
Issue Date2013
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1545-5017/
Citation
The 45th Congress of the International Society of Paediatric Oncology (SIOP 2013), Hong Kong, China, 25-28 September 2013. In Pediatric Blood & Cancer, 2013, v. 60 S3, p. 78, abstract no. P0102 How to Cite?
AbstractPURPOSE/OBJECTIVE: We aimed to review and compare the outcomes of children with acute myeloid leukemia (AML) who received allogeneic hematopoietic stem cell transplant (HSCT) from different types of donors. MATERIALS AND METHODS: We performed a retrospective review of the patient and transplant characteristics and transplant outcomes of children with AML who underwent allogeneic HSCT in our unit. RESULTS: We performed allogeneic HSCT for 42 children (26 males and 16 females) with AML in 1994-2012. The median age at HSCT was 9.2 years (range, 0.8 to 18.5 years). Sixteen children were transplanted in first complete remission, 19 in second remission, 1 in third remission, and 6 with non-remission. Donors were matched sibling (MS) (n ? 17), 1-antigen mismatched parent (MP) (n ? 2), matched unrelated donor (MUD) (n ? 11), or 4-6/6 HLA-matched unrelated cord blood (UCB) (n ? 12). Five-year overall survival (OS) and relapse-free survival (RFS) were better in patients who received UCB compared to MS, MUD, or MP (OS: 76.2% vs. 32.4% vs. 18.2% vs. 0%; RFS: 71.4% vs. 32.7% vs. 18.2% vs. 0%). The differences in OS and RFS among different types of donors were statistically significant after adjusting for age and remission status (p ? 0.007 for OS and p ? 0.037 for RFS). Transplant-related mortalities in UCB, MS, MUD, and MP were 0%, 17.6%, 72.7% and 50% respectively. CONCLUSIONS: Outcomes were favorable for pediatric AML patients who received unrelated cord blood transplant compared to other types of donors in our unit.
DescriptionThis journal suppl. entitled: Supplement: SIOP Abstratcs: 45th Congress of the International Society of Paediatric Oncology (SIOP) ... 2013
Poster Session - Myeloid leukemias - abstarct no. P-0102
Persistent Identifierhttp://hdl.handle.net/10722/193637
ISSN
2015 Impact Factor: 2.634
2015 SCImago Journal Rankings: 1.505

 

DC FieldValueLanguage
dc.contributor.authorCheuk, DKLen_US
dc.contributor.authorChiang, Aen_US
dc.contributor.authorHa, SYen_US
dc.contributor.authorChan, Gen_US
dc.date.accessioned2014-01-20T05:12:15Z-
dc.date.available2014-01-20T05:12:15Z-
dc.date.issued2013en_US
dc.identifier.citationThe 45th Congress of the International Society of Paediatric Oncology (SIOP 2013), Hong Kong, China, 25-28 September 2013. In Pediatric Blood & Cancer, 2013, v. 60 S3, p. 78, abstract no. P0102en_US
dc.identifier.issn1545-5009-
dc.identifier.urihttp://hdl.handle.net/10722/193637-
dc.descriptionThis journal suppl. entitled: Supplement: SIOP Abstratcs: 45th Congress of the International Society of Paediatric Oncology (SIOP) ... 2013-
dc.descriptionPoster Session - Myeloid leukemias - abstarct no. P-0102-
dc.description.abstractPURPOSE/OBJECTIVE: We aimed to review and compare the outcomes of children with acute myeloid leukemia (AML) who received allogeneic hematopoietic stem cell transplant (HSCT) from different types of donors. MATERIALS AND METHODS: We performed a retrospective review of the patient and transplant characteristics and transplant outcomes of children with AML who underwent allogeneic HSCT in our unit. RESULTS: We performed allogeneic HSCT for 42 children (26 males and 16 females) with AML in 1994-2012. The median age at HSCT was 9.2 years (range, 0.8 to 18.5 years). Sixteen children were transplanted in first complete remission, 19 in second remission, 1 in third remission, and 6 with non-remission. Donors were matched sibling (MS) (n ? 17), 1-antigen mismatched parent (MP) (n ? 2), matched unrelated donor (MUD) (n ? 11), or 4-6/6 HLA-matched unrelated cord blood (UCB) (n ? 12). Five-year overall survival (OS) and relapse-free survival (RFS) were better in patients who received UCB compared to MS, MUD, or MP (OS: 76.2% vs. 32.4% vs. 18.2% vs. 0%; RFS: 71.4% vs. 32.7% vs. 18.2% vs. 0%). The differences in OS and RFS among different types of donors were statistically significant after adjusting for age and remission status (p ? 0.007 for OS and p ? 0.037 for RFS). Transplant-related mortalities in UCB, MS, MUD, and MP were 0%, 17.6%, 72.7% and 50% respectively. CONCLUSIONS: Outcomes were favorable for pediatric AML patients who received unrelated cord blood transplant compared to other types of donors in our unit.-
dc.languageengen_US
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1545-5017/-
dc.relation.ispartofPediatric Blood & Canceren_US
dc.rightsPediatric Blood & Cancer. Copyright © John Wiley & Sons, Inc.-
dc.subjectMedical sciences-
dc.subjectOncology medical sciences-
dc.subjectPediatrics-
dc.titleFavorable outcomes of unrelated cord blood transplant for pediatric acute myeloid leukemia in Hong Kongen_US
dc.typeConference_Paperen_US
dc.identifier.emailCheuk, DKL: klcheuk@hkucc.hku.hken_US
dc.identifier.emailChiang, A: chiangak@hku.hken_US
dc.identifier.emailHa, SY: syha@hku.hken_US
dc.identifier.emailChan, G: gcfchan@hku.hken_US
dc.identifier.authorityChiang, A=rp00403en_US
dc.identifier.authorityChan, G=rp00431en_US
dc.identifier.doi10.1002/pbc.24719-
dc.identifier.hkuros227215en_US
dc.identifier.volume60-
dc.identifier.issueS3-
dc.identifier.spage78-
dc.identifier.epage78-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats